Vimarsana
Biggest News Aggregation in the World

Page 8 - Briggs Morrison News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Briggs Morrison. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Briggs Morrison Today - Breaking & Trending Today

CTC Capital Management LLC Buys New Shares in Digital Realty Trust, Inc. (NYSE:DLR) - Vimarsana News

CTC Capital Management LLC Buys New Shares in Digital Realty Trust, Inc. (NYSE:DLR)

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX – Get Rating) shares saw unusually-high trading volume on Thursday . Approximately 1,643,856 shares traded hands during trading, an increase of 101% from the previous session’s volume of 819,510 shares.The stock last traded at $20.35 and had previously closed at $19.97. Wall Street Analysts Forecast Growth Several equities research analysts recently […]

Tekla Capital Management LLC Invests $3 Million in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - Vimarsana News

Tekla Capital Management LLC Invests $3 Million in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

Tekla Capital Management LLC bought a new position in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX – Get Rating) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 117,717 shares of the company’s stock, valued at approximately $2,996,000. Tekla Capital Management LLC owned approximately 0.20% of […]

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Receives Consensus Recommendation of "Moderate Buy" from Analysts - Vimarsana News

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX – Get Rating) have been given an average recommendation of “Moderate Buy” by the eight research firms that are covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation and four have given a buy recommendation to the company. The average 1 year […]

Q2 2023 EPS Estimates for Syndax Pharmaceuticals, Inc. Cut by Analyst (NASDAQ:SNDX) - Vimarsana News

Q2 2023 EPS Estimates for Syndax Pharmaceuticals, Inc. Cut by Analyst (NASDAQ:SNDX)

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX – Get Rating) – Research analysts at HC Wainwright dropped their Q2 2023 earnings estimates for Syndax Pharmaceuticals in a report issued on Tuesday, May 9th. HC Wainwright analyst E. White now expects that the company will post earnings per share of ($0.70) for the quarter, down from their prior forecast […]

Syndax Pharmaceuticals (NASDAQ:SNDX) Given New $36.00 Price Target at HC Wainwright - Vimarsana News

Syndax Pharmaceuticals (NASDAQ:SNDX) Given New $36.00 Price Target at HC Wainwright

Syndax Pharmaceuticals (NASDAQ:SNDX – Get Rating) had its target price raised by HC Wainwright from $33.00 to $36.00 in a research report released on Tuesday morning, The Fly reports. HC Wainwright also issued estimates for Syndax Pharmaceuticals’ Q2 2023 earnings at ($0.70) EPS, Q3 2023 earnings at ($0.83) EPS, Q3 2023 earnings at ($0.83) EPS, […]

Source: wkrb13.com